Tirzepatide vs Retatrutide: Dual vs Triple Agonist Compared
Verdict Summary
Retatrutide's triple agonism (GIP + GLP-1 + glucagon) produced ~24% weight loss in Phase 2 trials, potentially exceeding tirzepatide. However, retatrutide is not yet FDA approved as of 2025.
Medical Disclaimer: This comparison is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer →
At a Glance
| Dimension | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism | GIP + GLP-1 dual agonist | GIP + GLP-1 + glucagon triple agonist |
| FDA Status | Approved (2022) | Phase 3 trials (2025) |
| Avg. Weight Loss | ~20-22% | ~24% (Phase 2) |
| Availability | Prescription only | Research compound / clinical trials |
Tirzepatide Deep Dive
Tirzepatide is the most effective approved weight loss medication as of 2025. Its dual GIP/GLP-1 mechanism produces superior outcomes to GLP-1 monotherapy, with ~20-22% average weight loss in the SURMOUNT trials.
How to Choose
Choose Tirzepatide if…
- •You want an FDA-approved treatment available now
- •You want the most clinically validated option
- •Insurance coverage is important
Choose Retatrutide if…
- •You are interested in clinical trial participation
- •You want the potentially most effective future option
- •You are following emerging research closely
Frequently Asked Questions
More Comparisons
BPC-157 vs TB-500
BPC-157 excels at localized tendon, ligament, and gut healing. TB-500 is better for systemic muscle recovery and widespread inflammation.
Semaglutide vs Tirzepatide
Tirzepatide produces greater average weight loss in clinical trials. Semaglutide has a longer post-market safety record. Both are excellent options.
Ipamorelin vs CJC-1295
Ipamorelin and CJC-1295 work through complementary mechanisms and are almost always used together rather than as alternatives.
Ozempic vs Wegovy
Ozempic and Wegovy both contain Semaglutide. The difference is FDA indication and maximum dose — Wegovy is approved for weight management at higher doses.
Mounjaro vs Zepbound
Mounjaro and Zepbound both contain Tirzepatide. Mounjaro is approved for Type 2 diabetes; Zepbound for obesity. The active ingredient is identical.
Selank vs Semax
Selank is primarily anxiolytic — it reduces anxiety and improves mood. Semax is primarily a cognitive enhancer — it boosts focus, memory, and BDNF. They are frequently combined.